Bernd Kasper

11.5k total citations
171 papers, 2.5k citations indexed

About

Bernd Kasper is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Bernd Kasper has authored 171 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Pulmonary and Respiratory Medicine, 79 papers in Oncology and 43 papers in Pathology and Forensic Medicine. Recurrent topics in Bernd Kasper's work include Sarcoma Diagnosis and Treatment (132 papers), Vascular Tumors and Angiosarcomas (46 papers) and Soft tissue tumor case studies (29 papers). Bernd Kasper is often cited by papers focused on Sarcoma Diagnosis and Treatment (132 papers), Vascular Tumors and Angiosarcomas (46 papers) and Soft tissue tumor case studies (29 papers). Bernd Kasper collaborates with scholars based in Germany, United Kingdom and Belgium. Bernd Kasper's co-authors include Peter Hohenberger, Philipp Ströbel, Gerlinde Egerer, Alessandro Gronchi, Winette T.A. van der Graaf, Antonia Dimitrakopoulou‐Strauss, Anthony D. Ho, Sebastian Bauer, Florian Haller and Saskia Litière and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Bernd Kasper

162 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bernd Kasper Germany 26 1.8k 1.1k 858 587 471 171 2.5k
Charlotte Benson United Kingdom 31 2.1k 1.2× 1.4k 1.4× 565 0.7× 431 0.7× 524 1.1× 127 3.1k
Palma Dileo United Kingdom 18 1.6k 0.9× 850 0.8× 499 0.6× 400 0.7× 445 0.9× 52 2.0k
M. Ouali France 19 1.4k 0.8× 957 0.9× 350 0.4× 338 0.6× 454 1.0× 46 1.8k
Alessandro Comandone Italy 25 2.3k 1.3× 1.4k 1.3× 913 1.1× 475 0.8× 539 1.1× 103 3.0k
Arthur P. Staddon United States 29 2.4k 1.4× 1.4k 1.4× 1.1k 1.3× 426 0.7× 482 1.0× 67 3.5k
B. Bui France 24 1.5k 0.9× 826 0.8× 580 0.7× 307 0.5× 372 0.8× 63 2.0k
Armelle Dufresne France 19 1.1k 0.6× 1.1k 1.0× 793 0.9× 481 0.8× 103 0.2× 103 2.2k
Roberta Sanfilippo Italy 27 2.1k 1.2× 1.4k 1.3× 487 0.6× 337 0.6× 932 2.0× 98 2.5k
James E. Butrynski United States 26 2.0k 1.2× 1.2k 1.1× 738 0.9× 434 0.7× 410 0.9× 52 3.3k
Olivier Collard France 16 1.1k 0.6× 681 0.6× 440 0.5× 206 0.4× 324 0.7× 67 1.6k

Countries citing papers authored by Bernd Kasper

Since Specialization
Citations

This map shows the geographic impact of Bernd Kasper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Kasper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Kasper more than expected).

Fields of papers citing papers by Bernd Kasper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernd Kasper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Kasper. The network helps show where Bernd Kasper may publish in the future.

Co-authorship network of co-authors of Bernd Kasper

This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Kasper. A scholar is included among the top collaborators of Bernd Kasper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Kasper. Bernd Kasper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Falkenhorst, Johanna, Philipp Ivanyi, Rainer Hamacher, et al.. (2025). Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial). Clinical Cancer Research. 31(19). 4059–4069.
2.
Coté, Gregory M., Sant P. Chawla, George D. Demetri, et al.. (2025). SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma. Future Oncology. 21(8). 943–951.
3.
Vincenzi, Bruno, Nam Bui, Palma Dileo, et al.. (2024). Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study.. Journal of Clinical Oncology. 42(16_suppl). 11556–11556. 1 indexed citations
4.
Kasper, Bernd, Noah Federman, Peter Reichardt, et al.. (2024). Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses.. Journal of Clinical Oncology. 42(16_suppl). 11558–11558. 3 indexed citations
5.
Singer, Susanne, Leopold Hentschel, Stephan Richter, et al.. (2023). Working situation and burden of work limitations in sarcoma patients: results from the multi-center prospective PROSa study. Journal of Cancer Research and Clinical Oncology. 149(9). 6009–6021. 3 indexed citations
6.
7.
Kyriazoglou, Anastasios, Olivier Mir, Bernd Kasper, et al.. (2022). Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 ‘CaboGIST’. Acta Oncologica. 61(6). 663–668. 1 indexed citations
8.
Spolverato, Gaya, Giulia Capelli, Bernd Kasper, & Mrinal M. Gounder. (2022). Management of Desmoid Tumors. Surgical Oncology Clinics of North America. 31(3). 447–458. 2 indexed citations
9.
Kasper, Bernd, Lorenzo D’Ambrosio, Elizabeth J. Davis, et al.. (2022). What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?. Current Treatment Options in Oncology. 23(3). 439–449. 6 indexed citations
10.
Penel, Nicolas, Bernd Kasper, & Winette T.A. van der Graaf. (2021). Desmoid-type fibromatosis: toward a holistic management. Current Opinion in Oncology. 33(4). 309–314. 7 indexed citations
11.
12.
Pignochino, Ymera, Giovanni Crisafulli, G Giordano, et al.. (2021). PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study. Cancers. 13(24). 6295–6295. 2 indexed citations
13.
Kasper, Bernd, Chandrajit P. Raut, & Alessandro Gronchi. (2020). Desmoid tumors: To treat or not to treat, That is the question. Cancer. 126(24). 5213–5221. 39 indexed citations
14.
Kasper, Bernd, Viktor Gruenwald, Peter Reichardt, et al.. (2017). Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). European Journal of Cancer. 76. 60–67. 83 indexed citations
15.
Balincourt, Christine de, Denis Lacombe, Corneel Coens, et al.. (2017). Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC). European Journal of Cancer. 86. 91–100. 13 indexed citations
16.
17.
Kasper, Bernd. (2015). Systemic Treatment Approaches for Sporadic Desmoid-Type Fibromatosis: Scarce Evidence and Recommendations. Oncology Research and Treatment. 38(5). 244–248. 18 indexed citations
18.
Kasper, Bernd, Antonia Dimitrakopoulou‐Strauss, Lothar R. Pilz, et al.. (2013). Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib. BioMed Research International. 2013. 1–7. 18 indexed citations
19.
Erben, Philipp, Daniel Nowak, Christian Sauer, et al.. (2012). Molecular Analysis of Desmoid Tumors with a High-Density Single-Nucleotide Polymorphism Array Identifies New Molecular Candidate Lesions. Oncology Research and Treatment. 35(11). 684–689. 2 indexed citations
20.
Kasper, Bernd, Philipp Ströbel, & Peter Hohenberger. (2011). Desmoid Tumors: Clinical Features and Treatment Options for Advanced Disease. The Oncologist. 16(5). 682–693. 193 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charlotte Benson Breakdown of academic impact, for papers by Palma Dileo Breakdown of academic impact, for papers by M. Ouali Breakdown of academic impact, for papers by Alessandro Comandone Breakdown of academic impact, for papers by Arthur P. Staddon Breakdown of academic impact, for papers by B. Bui Breakdown of academic impact, for papers by Armelle Dufresne Breakdown of academic impact, for papers by Roberta Sanfilippo Breakdown of academic impact, for papers by James E. Butrynski Breakdown of academic impact, for papers by Olivier Collard
Rankless by CCL
2026